Predictors of suboptimal surgical cytoreduction in women with advanced epithelial ovarian cancer treated with initial chemotherapy

International Journal of Gynecological Cancer

Volumn 18, Issue 4, 2008, Pages 629-636

  Bland, A E ^a,b   Everett, E N ^a   Pastore, L M ^a   Andersen, W A ^a   Taylor Jr , P T ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chemotherapy; Initial chemotherapy; Neoadjuvant chemotherapy; Ovarian cancer; Suboptimal cytoreduction

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; PLATINUM DERIVATIVE; TAXANE DERIVATIVE;

ADULT; ADVANCED CANCER; ALGORITHM; ARTICLE; BLADDER; CANCER PATIENT; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CYTOREDUCTIVE SURGERY; DIAPHRAGM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MESENTERY DISEASE; MORBIDITY; MULTIPLE CYCLE TREATMENT; OVARY CANCER; PERITONEUM; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SMALL INTESTINE DISEASE; SPLEEN; TREATMENT OUTCOME; TREATMENT RESPONSE;

ALGORITHMS; ANTINEOPLASTIC AGENTS; CA-125 ANTIGEN; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; NEOPLASM, RESIDUAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 47649097938     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2007.01114.x     Document Type: Article

References (35)

1. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002 20 : 1248 59.
2. Chi DS, Franklin CC, Levine DA et al. Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach. Gynecol Oncol 2004 94 : 650 4.
3. Schwartz PE. Neoadjuvant chemotherapy for the management of ovarian cancer. Best Pract Res Clin Obstet Gynaecol 2002 16 : 585 96.
4. Ushijima K, Ota S, Komai K et al. Clinical assessment of neoadjuvant chemotherapy and interval cytoreductive surgery for unresectable advanced ovarian cancer. Int Surg 2002 87 : 185 90.
5. Vrscaj MU, Rakar S. Neoadjuvant chemotherapy for advanced epithelial ovarian carcinoma: a retrospective case-control study. Eur J Gynaecol Oncol 2002 23 : 405 10.
6. Kayikcioglu F, Kose MF, Boran N, Caliskan E, Tulunay G. Neoadjuvant chemotherapy or primary surgery in advanced epithelial ovarian carcinoma. Int J Gynecol Cancer 2001 11 : 466 70.
7. Kuhn W, Rutke S, Spathe K et al. Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma. Cancer 2001 92 : 2585 91.
8. Vergote IB, De Wever I, Decloedt J, Tjalma W, Van Gramberen M, van Dam P. Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer. Semin Oncol 2000 27 (Suppl. 7 31 6.
9. Everett EN, French AE, Stone RL et al. Initial chemotherapy followed by surgical cytoreduction for the treatment of stage III/IV epithelial ovarian cancer. Am J Obstet Gynecol 2006 195 : 568 74 discussion 574 6.
10. Bristow RE, Duska LR, Lambrou NC et al. A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography. Cancer 2000 89 : 1532 40.
11. Brockbank EC, Ind TE, Barton DP et al. Preoperative predictors of suboptimal primary surgical cytoreduction in women with clinical evidence of advanced primary epithelial ovarian cancer. Int J Gynecol Cancer 2004 14 : 42 50.
12. Chi DS, Venkatraman ES, Masson V, Hoskins WJ. The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma. Gynecol Oncol 2000 77 : 227 31.
13. Cooper BC, Sood AK, Davis CS et al. Preoperative CA 125 levels: an independent prognostic factor for epithelial ovarian cancer. Obstet Gynecol 2002 100 : 59 64.
14. Dowdy SC, Mullany SA, Brandt KR, Huppert BJ, Cliby WA. The utility of computed tomography scans in predicting suboptimal cytoreductive surgery in women with advanced ovarian carcinoma. Cancer 2004 101 : 346 52.
15. Gemer O, Segal S, Kopmar A. Preoperative CA-125 level as a predictor of non optimal cytoreduction of advanced epithelial ovarian cancer. Acta Obstet Gynecol Scand 2001 80 : 583 5.
16. Meyer JI, Kennedy AW, Friedman R, Ayoub A, Zepp RC. Ovarian carcinoma: value of CT in predicting success of debulking surgery. AJR Am J Roentgenol 1995 165 : 875 8.
17. Nelson BE, Rosenfield AT, Schwartz PE. Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma. J Clin Oncol 1993 11 : 166 72.
18. Chi DS, Liao JB, Leon LF et al. Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecol Oncol 2001 82 : 532 7.
19. Martinez-Said H, Rincon DG, Montes de Oca MM, Ruiz GC, Ponce JL, Lopez-Graniel CM. Predictive factors for irresectability in advanced ovarian cancer. Int J Gynecol Cancer 2004 14 : 423 30.
20. Le T, Krepart GV, Lotocki RJ, Heywood MS. Does debulking surgery improve survival in biologically aggressive ovarian carcinoma? Gynecol Oncol 1997 67 : 208 14.
21. Hoskins WJ, McGuire WP, Brady MF et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 1994 170 : 974 9 discussion 979 80.
22. Griffiths CT, Parker LM, Fuller AF Jr. Role of cytoreductive surgical treatment in the management of advanced ovarian cancer. Cancer Treat Rep 1979 63 : 235 40.
23. McCreath WA, Chi DS. Surgical cytoreduction in ovarian cancer. Oncology (Williston Park) 2004 18 : 645 53 discussion 653 4, 656, 658.
24. Bristow RE, Chi DS. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecol Oncol 2006 103 : 1070 6.
25. Qayyum A, Coakley FV, Westphalen AC, Hricak H, Okuno WT, Powell B. Role of CT and MR imaging in predicting optimal cytoreduction of newly diagnosed primary epithelial ovarian cancer. Gynecol Oncol 2005 96 : 301 6.
26. Tempany CM, Zou KH, Silverman SG, Brown DL, Kurtz AB, McNeil BJ. Staging of advanced ovarian cancer: comparison of imaging modalities-report from the Radiological Diagnostic Oncology Group. Radiology 2000 215 : 761 7.
27. Pannu HK, Horton KM, Fishman EK. Thin section dual-phase multidetector-row computed tomography detection of peritoneal metastases in gynecologic cancers. J Comput Assist Tomogr 2003 27 : 333 40.
28. Tate S, Hirai Y, Takeshima N, Hasumi K. CA125 regression during neoadjuvant chemotherapy as an independent prognostic factor for survival in patients with advanced ovarian serous adenocarcinoma. Gynecol Oncol 2005 96 : 143 9.
29. Hawkins RE, Roberts K, Wiltshaw E, Mundy J, Fryatt IJ, McCready VR. The prognostic significance of the half-life of serum CA 125 in patients responding to chemotherapy for epithelial ovarian carcinoma. Br J Obstet Gynaecol 1989 96 : 1395 9.
30. Rosman M, Hayden CL, Thiel RP et al. Prognostic indicators for poor risk epithelial ovarian carcinoma. Cancer 1994 74 : 1323 8.
31. Yedema CA, Kenemans P, Voorhorst F et al. CA 125 half-life in ovarian cancer: a multivariate survival analysis. Br J Cancer 1993 67 : 1361 7.
32. Deffieux X, Castaigne D, Pomel C. Role of laparoscopy to evaluate candidates for complete cytoreduction in advanced stages of epithelial ovarian cancer. Int J Gynecol Cancer 2006 16 (Suppl. 1 35 40.
33. Fagotti A, Fanfani F, Ludovisi M et al. Role of laparoscopy to assess the chance of optimal cytoreductive surgery in advanced ovarian cancer: a pilot study. Gynecol Oncol 2005 96 : 729 35.
34. Angioli R, Palaia I, Zullo MA et al. Diagnostic open laparoscopy in the management of advanced ovarian cancer. Gynecol Oncol 2006 100 : 455 61.
35. Vergote I, Marquette S, Amant F, Berteloot P, Neven P. Port-site metastases after open laparoscopy: a study in 173 patients with advanced ovarian carcinoma. Int J Gynecol Cancer 2005 15 : 776 9.